NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT05563272 2025-07-10STARBURSTTelix Pharmaceuticals (Innovations) Pty LimitedPhase 2 Terminated11 enrolled